Frontiers in Oncology (Mar 2022)
Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
- Victoria Heredia-Soto,
- Victoria Heredia-Soto,
- Javier Escudero,
- María Miguel,
- Patricia Ruiz,
- Alejandro Gallego,
- Alberto Berjón,
- Alberto Berjón,
- Alicia Hernández,
- Alicia Hernández,
- Marta Martínez-Díez,
- Shuyu Zheng,
- Jing Tang,
- David Hardisson,
- David Hardisson,
- David Hardisson,
- David Hardisson,
- Jaime Feliu,
- Jaime Feliu,
- Jaime Feliu,
- Jaime Feliu,
- Andrés Redondo,
- Andrés Redondo,
- Andrés Redondo,
- Marta Mendiola,
- Marta Mendiola
Affiliations
- Victoria Heredia-Soto
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Victoria Heredia-Soto
- Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Javier Escudero
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- María Miguel
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Patricia Ruiz
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Alejandro Gallego
- Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
- Alberto Berjón
- Department of Pathology, Hospital Universitario La Paz, Madrid, Spain
- Alberto Berjón
- Molecular Pathology and Therapeutic Targets Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Alicia Hernández
- Department of Obstetrics and Gynecology, Hospital Universitario La Paz, Madrid, Spain
- Alicia Hernández
- Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Marta Martínez-Díez
- Cell Biology Department, Research and Development, Oncology Business Unit, Pharmamar, Madrid, Spain
- Shuyu Zheng
- Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Jing Tang
- Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- David Hardisson
- Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- David Hardisson
- Department of Pathology, Hospital Universitario La Paz, Madrid, Spain
- David Hardisson
- Molecular Pathology and Therapeutic Targets Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- David Hardisson
- Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Jaime Feliu
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Jaime Feliu
- Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Jaime Feliu
- Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
- Jaime Feliu
- 0Cátedra UAM-ANGEM, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Andrés Redondo
- Translational Oncology Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Andrés Redondo
- Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
- Andrés Redondo
- 0Cátedra UAM-ANGEM, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Marta Mendiola
- Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Marta Mendiola
- Molecular Pathology and Therapeutic Targets Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- DOI
- https://doi.org/10.3389/fonc.2022.862321
- Journal volume & issue
-
Vol. 12
Abstract
Ovarian cancer (OC) is a life-threatening tumor and the deadliest among gynecological cancers in developed countries. First line treatment with a carboplatin/paclitaxel regime is initially effective in the majority of patients, but most advanced OC will recur and develop drug resistance. Therefore, the identification of alternative therapies is needed. In this study, we employed a panel of high-grade serous ovarian cancer (HGSOC) cell lines, in monolayer and three-dimensional cell cultures. We evaluated the effects of a novel tubulin-binding agent, plocabulin, on proliferation, cell cycle, migration and invasion. We have also tested combinations of plocabulin with several drugs currently used in OC in clinical practice. Our results show a potent antitumor activity of plocabulin, inhibiting proliferation, disrupting microtubule network, and decreasing their migration and invasion capabilities. We did not observe any synergistic combination of plocabulin with cisplatin, doxorubicin, gemcitabine or trabectedin. In conclusion, plocabulin has a potent antitumoral effect in HGSOC cell lines that warrants further clinical investigation.
Keywords
- plocabulin (PM060184)
- microtubule inhibitor
- high-grade serous ovarian cancer (HGSOC)
- 3D cell culture
- drug testing